A Reliable and Valid Instrument to Measure the Signs and Symptoms of Urogenital Atrophy in Breast Cancer Survivors

2.50
Hdl Handle:
http://hdl.handle.net/10755/148413
Type:
Presentation
Title:
A Reliable and Valid Instrument to Measure the Signs and Symptoms of Urogenital Atrophy in Breast Cancer Survivors
Abstract:
A Reliable and Valid Instrument to Measure the Signs and Symptoms of Urogenital Atrophy in Breast Cancer Survivors
Conference Sponsor:Sigma Theta Tau International
Conference Year:2009
Author:Lester, Joanne, PhD, CRNP, ANP-BC, AOCN
P.I. Institution Name:James Cancer Hospital
Title:Research Scientist, Nurse Practitioner, Clinical Assistant Professor
[Scientific Session Presentation] Urogenital atrophy is a common side effect in menopausal women.  Menopausal breast cancer survivors are especially challenged, as cancer treatment(s) can exacerbate the symptoms with significant hormonal alterations.  There are over 2.3 million breast cancer survivors in the United States; when sampled, over 60% report at least one symptom related to urogenital atrophy.  Common hormonal interventions are not recommended for this population due to the concern of recurrent disease. The theory of unpleasant symptoms provides a framework to study this biopsychosocial phenomena, with attention to physiologic, psychologic, and situational effects on the symptom experience.  An instrument to effectively measure the signs and symptoms of urogenital atrophy did not exist in the literature.  Therefore, measurement of the potential response to treatment was difficult and without standardization.  A reliable and valid instrument to measure the symptoms of urogenital atrophy in breast cancer survivors was developed in 2008.  Factor analysis identified three common domains with ten common symptom dimensions, resulting in a 16-item questionnaire.  This instrument allowed the survivors to self-report urologic, genital, and sexual symptoms, regardless of partner status, gender, sexual activity, and/or practice of penile vaginal intercourse.  Additional research was performed in 2009 to identify a reliable and valid sign of urogenital atrophy.  Combined, these studies result in a reliable and valid instrument to measure and document the signs and symptoms of urogenital atrophy in breast cancer survivors.Dissemination of these study results and this newly-designed instrument is vital to the accurate assessment and measurement of urogenital atrophy, as care of breast cancer survivors is not limited to the oncology health care team. The number of breast cancer survivors is increasing exponentially due to early detection efforts, improvement treatments, and decreased systemic hormonal usage.  Therefore, nurses must be able to identify the common signs and symptoms of urogenital atrophy and provide accurate documentation.  Future research to identify effective, non-hormonal interventions is warranted.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleA Reliable and Valid Instrument to Measure the Signs and Symptoms of Urogenital Atrophy in Breast Cancer Survivorsen_GB
dc.identifier.urihttp://hdl.handle.net/10755/148413-
dc.description.abstract<table><tr><td colspan="2" class="item-title">A Reliable and Valid Instrument to Measure the Signs and Symptoms of Urogenital Atrophy in Breast Cancer Survivors</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2009</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Lester, Joanne, PhD, CRNP, ANP-BC, AOCN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">James Cancer Hospital</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Research Scientist, Nurse Practitioner, Clinical Assistant Professor</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">joanne.lester@osumc.edu</td></tr><tr><td colspan="2" class="item-abstract">[Scientific Session Presentation] Urogenital atrophy is a common&nbsp;side effect&nbsp;in menopausal women.&nbsp;&nbsp;Menopausal breast cancer survivors&nbsp;are especially&nbsp;challenged, as cancer treatment(s) can exacerbate the symptoms with significant hormonal alterations.&nbsp; There are over 2.3 million breast cancer survivors in the United States; when sampled, over 60%&nbsp;report at least one symptom related to urogenital atrophy.&nbsp; Common hormonal interventions are not recommended for this population due to the concern of recurrent disease. The theory of unpleasant symptoms provides a framework to&nbsp;study this&nbsp;biopsychosocial&nbsp;phenomena, with attention to physiologic, psychologic, and situational effects on the symptom experience.&nbsp; An instrument to effectively measure the signs and symptoms of urogenital atrophy did not exist in the literature.&nbsp; Therefore, measurement of the potential response to treatment&nbsp;was difficult and&nbsp;without standardization.&nbsp; A reliable and valid instrument to measure the&nbsp;symptoms of urogenital atrophy in breast cancer survivors was developed in 2008.&nbsp; Factor analysis identified three common&nbsp;domains with ten&nbsp;common symptom dimensions,&nbsp;resulting in a 16-item questionnaire.&nbsp; This instrument allowed the survivors to self-report urologic, genital, and sexual symptoms, regardless of partner status, gender, sexual activity, and/or practice of penile vaginal intercourse.&nbsp; Additional research was performed in 2009 to&nbsp;identify a reliable and valid sign of urogenital atrophy.&nbsp; Combined, these studies&nbsp;result in a reliable and valid instrument to measure and document the&nbsp;signs and symptoms of urogenital atrophy in breast cancer survivors.Dissemination of these study results and this newly-designed instrument is vital to the accurate&nbsp;assessment and measurement of urogenital atrophy, as care of&nbsp;breast cancer survivors is not limited to the oncology health care team. The number of breast cancer survivors is increasing exponentially due to early detection efforts, improvement treatments, and decreased systemic hormonal usage.&nbsp;&nbsp;Therefore, nurses must be able to identify the common signs and symptoms of urogenital atrophy and provide accurate documentation.&nbsp; Future research to identify effective, non-hormonal interventions is warranted.</td></tr></table>en_GB
dc.date.available2011-10-26T09:44:47Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T09:44:47Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.